Thyroid hormone, 3, 3 0 , 5-triiodo-L-thyronine (T 3 ), mediates cell growth, development and differentiation by binding to its nuclear receptors (TRs). The role of TRs in cancer is still undefined. Notably, hyperthyroxinemia has been reported to influence the rate of colon cancer in an experimental model of carcinogenesis in rats. Previous microarray analysis revealed that cathepsin H (CTSH) is upregulated by T 3 in HepG2-TR cells. We verified that mRNA and protein expression of CTSH are induced by T 3 in HepG2-TR cells and in thyroidectomized rats following administration of T 3 . The possible thyroid hormone-responsive elements of the CTSH promoter localized to the nucleotides -2038 to -1966 and -1565 to -1501 regions. An in vitro functional assay showed that CTSH can increase metastasis. J7 cells overexpressing CTSH were inoculated into severe combined immunedeficient mice and these J7-CTSH mice displayed a greater metastatic potential than did J7-control mice. The clinicopathologic significance of CTSH expression in hepatocellular carcinoma (HCC) was also investigated. The CTSH overexpressing in HCC was associated with the presence of microvascular invasion (P ¼ 0.037). The microvascular invasion characteristic is closely related to our in vitro characterization of CTSH function. Our results show that T 3 -mediated upregulation of CTSH led to matrix metallopeptidase or extracellular signal-regulated kinase activation and increased cell migration. This study demonstrated that CTSH overexpression in a subset hepatoma may be TR dependent and suggests that this overexpression has an important role in hepatoma progression.
Introduction
Thyroid hormone (3, 3 0 , 5-triiodo-L-thyronine; T 3 ) is a potent mediator of many physiological processes including embryonic development, cell differentiation, metabolism and the regulation of cell proliferation (Huang et al., 2008) . Two TR genes, THRA and THRB, have been identified and mapped to human chromosomes 17 and 3, respectively (Lazar, 1993; Yen, 2001 ). The liver is a typical target organ for T 3 . Equal amounts of TRa1 and TRb1 proteins are expressed in human hepatocytes (Chamba et al., 1996) . However, the mechanisms involved in the regulation of liver-specific genes by TRa1 and TRb1 have not been elucidated.
Evidence that TRs might be involved in carcinogenesis came from studies on v-erbA protein (Thormeyer and Baniahmad, 1999) , thus, v-erbA antagonizes TR function via competition for response elements or coactivators and ligand-dependent transcriptional activation (Yen et al., 1994) . That TRs can have an important role in tumor transformation was further verified by aberrant expression and mutations of TRs in various human cancers including pituitary tumors (Ando et al., 2001) , hepatocellular carcinomas (HCCs) (Lin et al., 2001) , thyroid cancers (PuzianowskaKuznicka et al., 2002) and renal clear cell carcinomas (Rosen and Privalsky, 2009) . Transgenic mice (TRb PV/PV ), harboring a PV mutation originally identified in a patient with thyroid hormone resistance, spontaneously developed thyroid cancer (Suzuki et al., 2002) . This study showed that TRb could act as a tumor suppressor. Recently, Zhu et al. (2010) reported that mice devoid of functional TRs (TRa1
TRb1
À/À ) spontaneously develop follicular thyroid cancer and metastases in the lung. TRs could function as tumor suppressors in such mice. Besides their suppressor role, TRs enhanced tumor progression in other studies. Thyroid hormones stimulate the proliferation of several cancer cell types including those from the pituitary (Barrera-Hernandez et al., 1999) , gliomas (Davis et al., 2006) , breast cancers (Hall et al., 2008) and prostate cancers (Tsui et al., 2008) . Thyroid hormone and the TRa1 receptor control epithelial cell proliferation and the expression of components of the Wnt pathway (Plateroti et al., 2006) .
Various proteases are implicated in cancer progression by degrading the basement membrane and extracellular matrix in a cascade-like manner (Mohamed and Sloane, 2006; Wilson and Singh, 2008) . Cysteine cathepsins are a family of lysosomal proteases that are often upregulated in various human cancers, and these proteases have been implicated in distinct tumorigenic processes, such as angiogenesis, proliferation, apoptosis and invasion (Berdowska, 2004; Joyce and Hanahan, 2004; Gocheva and Joyce, 2007) . Cysteine cathepsin proteases have recently emerged as enzymes that are active in cancer development, and cysteine cathepsin inhibitors have been proposed as anticancer agents (Palermo and Joyce, 2008) . There is increasing evidence that the expression of cathepsin H (CTSH) is increased in disease states including breast carcinoma (Gabrijelcic et al., 1992) , melanoma (Kos et al., 1997) , glioma (Sivaparvathi et al., 1996) , and colorectal and prostate carcinoma (del Re et al., 2000) .
Although several individual target genes have been studied in the liver, a large-scale profile of the target genes regulated by thyroid hormone has not been undertaken. CTSH gene expression was induced by T 3 in HepG2-TRa cells identified from oligonucleotide microarrays. CTSH and other proteases may be involved in the destruction of extracellular matrix components, leading to cancer proliferation, migration and metastasis (Tsushima et al., 1991) . However, elucidation of the underlying mechanisms by which T 3 regulated requires further study. Previous reports have shown that TRs are potent inducer of tumorigenesis (Plateroti et al., 2006; Chen et al., 2008a; Kress et al., 2009) . In this study, we report that the T 3 /TR controls the transcription of the CTSH gene and that T 3 -mediated cell migration appears to involve CTSH.
Results
Cathepsin mRNA is regulated by T 3 in the HepG2-TR cell line We used isogenic HepG2 cell lines that consistently express wild-type TRa1 (HepG2-TRa1#1, #2) and TRb1 (HepG2-TRb1). As a control, HepG2 cells were transfected with the empty vector, yielding a cell line expressing the Neo protein (HepG2-Neo cells). In the four HepG2 cell lines investigated in this study, HepG2-TRa1#1, -TRa1#2, -TRb1 and -Neo, overexpression of TR protein was approximately 10-, 3.3-and 2.5-fold that of the HepG2-Neo control cell line (data not shown). Previously, complementary DNA-microarrays were performed to identify the target genes regulated by T 3 in a hepatoma cell line-overexpressing TRa1 (HepG2-TRa1) (Shih et al., 2004) . That study demonstrated that 148 of the 7597 genes represented were positively regulated by T 3 , including those encoding fibrinogen, fibronectin, transferrin and several other coagulation factor system components. Recently, oligonucleotide microarrays were carried out to identify more TR-target genes. Some of the results have been published including the identification of FURIN (Chen et al., 2008a) , SPON2 , MATA1A (Wu et al., 2010) , SULT2A1 (Huang et al., 2006) and AKR1B1 (Liao et al., 2009) . Supplementary Table S1 lists several cancer-related genes, including those encoding cathepsin proteases positively regulated by T 3 .
We first used oligonucleotide microarrays to identify the genes induced by T 3 in HepG2-TRa cells. Upregulation of cathepsin cysteine proteases was identified and the result was verified by quantitative reverse transcription-PCR. Several human cysteine cathepsins (CTSH, CTSB, CTSS and CTSL) were induced by 3.2-8.6 times after the incubation of HepG2-TRa1#1 cells with 10 nM T 3 for 72 h (Supplementary Figure S1) . However, the mRNA levels of cysteine proteases, such as CTSV, were not induced by T 3 .
Northern blot analysis was used to assess further the response of CTSH mRNA expression to the exogenous addition of T 3 . A 1.47-kb CTSH transcript was identified in HepG2-TRa1#1 cells (Figure 1a ). The CTSH mRNA levels were induced by 3-4 times after incubation of HepG2-TRa1#1 cells with 10 nM T 3 for 48 h. A similar induction was observed in HepG2-TRa1#2 and -TRb1 cells. As a control, HepG2 cells were transfected with the empty vector, yielding a cell line expressing the Neo protein (HepG2-Neo cells).
T 3 upregulates expression of CTSH protein in HepG2-TR cells The effect of TRs on the degree of CTSH protein expression in HepG2 isogenic cell lines was studied ( Figure 1b ). CTSH is synthesized as an inactive proenzyme (41 kDa, upper arrow), which is then processed proteolytically to an active single chain, mature form (28 kDa, lower arrow) within the endosomes/lysosomes (Turk et al., 2001) . The incubation results indicated that T 3 increased the amount of 28-kDa CTSH protein in the HepG2-TRa1#1, -TRa1#2 and -TRb1 cells. The CTSH protein levels increased after incubation of HepG2-TRa1#1, -TRa1#2 and -TRb1 cells with 1 or 10 nM T 3 for 24-72 h. These results show that the effect of T 3 on the CTSH protein level in TRa1-overexpressing cells is time and dose dependent. Immunoblot analysis showed that incubation of control HepG2-Neo cells, which did not express detectable endogenous TR proteins, in 10 nM T 3 for 24-72 h did not increase the CTSH protein level significantly. However, the CTSH proenzyme was affected marginally by T 3 .
To analyze whether cathepsin is secreted into the culture medium, the HepG2-TR stable cell line was incubated in serum-free medium, and the medium was collected at 24 and 48 h. Analysis using anti-CTSH antibodies revealed a major extracellular product with an apparent molecular mass of 41 kDa (Supplementary Figure S2 ). This product was upregulated markedly in HepG2-TR cells incubated in media containing varying levels of T 3 for 24 and 48 h. CTSH protein level did not increase significantly in HepG2-Neo cells incubated in 10 nM T 3 for 24-48 h.
Similar results were observed in the other HCC cell line, Huh7 cells, which expressed detectable endogenous TR proteins: 10 or 100 nM T 3 increased CTSH mRNA and protein expression by 1.5-2 times in Huh7 cells at 48 h (Figures 1c and d) . The induction of extracellular CTSH protein was also observed in Huh7 cells (Figure 1d ).
T 3 induces expression of CTSH at the transcriptional level Promoter activity assays were performed to determine whether the regulation of CTSH expression by T 3 occurs at the transcriptional level. The nucleotide À2723 to þ 52 upstream region of CTSH was inserted upstream to a minimal thymidine kinase promoter to create a luciferase-based reporter plasmid. A series of pA3TK-luc reporter constructs containing progressively shorter fragments of CTSH 5 0 -flanking DNA were co-transfected with pcDNA-TRa1 in HepG2 cells (Figure 2a) . Increases of 3.67 and 8.16 times in the-2723 to þ 52 bp CTSH promoter activity were stimulated by 10 and 100 nM T 3 , respectively. A bioinformatics search revealed putative TREs in the CTSH promoter. Therefore, serially deleted mutants were also constructed from the CTSH fragment to identify the region targeted by TR. Treatment with 10 or 100 nM T 3 increased the activity of the CTSH deletion mutants (À2038 to À1801, À1739 to À1501, À1685 to À1501 and À1565 to À1415) compared with the T 3 -free condition. 
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The possible TREs located to the À2038 to À1801 and À1565 to À1415 constructs. Transfection analysis showed that two possible TREs (À2038 to À1801 and À1565 to À1415) in the upstream region of human CTSH were responsible for T 3 -induced human CTSH gene transcription. Mutations in the two TRE sequences of the CTSH promoter-caused loss of the TR/T 3 -stimulated CTSH promoter activity. These results indicate that the two possible TREs of the CTSH promoter are located in the À2038 to À1801 and À1565 to À1415 regions.
We used an electrophoretic mobility shift assay (EMSA) to investigate whether TRs bind directly to the two possible TREs of the CTSH promoter (Figure 2b ). Reactions performed with [a-32 P]-labeled À2038 to À1966 (lanes 1-16) and À1565 to À1501 (lanes 17-32) fragments of in vitro-translated TRa1/b1 and RXRa proteins produced one predominant band (lanes 4, 11, 20 and 27) . This band was supershifted by TR antibody (lanes 5, 12, 21 and 28) but not by control antibody (MOPC21; lanes 6, 13, 22 and 29). This band was competed out by adding a 2-or 10-times molar excess of cold probe (compare lanes 7 and 8; 14 and 15; 23 and 24; 30 and 31). However, mutations in the TREs in the -2038 to -1966 and -1565 to -1501 regions caused loss of the TR-binding activity (lanes 9, 16, 25 and 32). TR and RXR proteins form a complex with TREs located in the CTSH promoter TR proteins also bound to the two TREs of the CTSH promoter when HepG2-TRa nuclear extracts were used ( Figure 3a) . Briefly, one predominant band was detected (lanes 2 and 10) when using [a-32 P]-labeled -2038 to -1966 and -1565 to -1501 fragments. This band was specifically supershifted by antibody to the TR (lanes 4 and 12) or RXRa (lanes 5 and 13) but not by the control antibody (lanes 3 and 11). The band could be competed out by adding a 2-or 10-times molar excess of specific cold probe (compare lanes 6 and 7, and 14 and 15) but not by nonspecific cold probe (lane 8 and 16). The promoter assay and EMSA findings suggest that TRs activate CTSH gene transcription by binding directly to the TRE sites located in the À2038 to À1966 and À1565 to À1501 regions.
In the chromatin immunoprecipitation (ChIP) assay, the TR proteins associated with the two TRE regions of the CTSH promoter in vivo (Figure 3b ). Both TRa1/b1 and RXRa were clearly recruited to the TRE-binding site, whereas control immunoglobulin G produced only background levels. The positive control (human furin gene containing TRE) showed detectable bands using antibodies to RXRa or TRs. However, no band was detected using a primer set for the negative control (human glyceraldehyde 3-phosphate dehydrogenase (GAPDH) gene). The ChIP assay revealed that the TRs and RXRa complex bound to the CTSH promoter.
T 3 induces CTSH mRNA and protein expression in vivo Two groups of 6-week-old male Sprague-Dawley rats (n ¼ 6) underwent surgical thyroidectomies (TX) to determine the in vivo response of CTSH to T 3 treatment. One group (three rats per group) was injected with T 3 daily for 2 weeks (TX þ T 3 ), the second group did not receive T 3 injections (TX) and the third group included the control sham-operated rats (n ¼ 3). The rats were killed at the end of the experiment, and T 3 and TSH concentrations were measured in the serum. The livers were removed and cell lysates were prepared for western blot analysis. The serum T 3 level in the TX group was about 0.016 times (7.6 vs 489 ng/dl) that in the group that underwent T 3 treatment (TX þ T 3 ). The TSH level in the TX group was 226 times (3.16 vs 0.014 mg/ml) that in the T 3 -treated group. The T 3 and TSH serum levels in the sham group were around 40 ng/dl and 2.23 mg/ml, respectively.
Western blot analysis of cell lysates demonstrated that CTSH protein levels were much higher in the rats administered T 3 than the TX group. The expression of CTSH mRNA and protein was higher in the TX þ T 3 or sham group than in the TX group (Figures 4a and b) . Further, we verified the in vivo response of the CTSH gene to T 3 showing that CTSH mRNA and proteins were upregulated in thyroidectomized rats after T 3 treatment. These results help elucidate the regulation of CTSH expression by thyroid hormones. The common proteolytic degradation by lysosomal cysteine proteinases could be a general process (Dickinson, 2002) . Besides their role inside lysosomes, cysteine proteases degrade proteins outside lysosomes. It is required to clarify the other role of CTSH regulated by T 3 in normal liver in the future.
The clinicopathologic significance of CTSH expression in HCC was also investigated. A total of 93 patients with HCC were enrolled consecutively in this study. An equal amount (30 mg) of protein from each specimen was loaded for electrophoresis and western blot analysis. Actin was used as an equal loading control. CTSH proteins were detected in most of the cancerous tissues. The results from 15 representative paired HCC specimens are shown in Figure 4c , which shows increased CTSH expression and concomitantly increased most of the TR proteins expression in HCC tissues. The percentage of all paired samples with upregulated CTSH relative to the matched noncancerous adjacent tissues (B1 cm distant from HCC) was 64.5% (60/93) in the cancerous tissues. Both TRa1 and TRb1 expression was Figure 2 . A upstream region À2264 to À2054 in the CTSH promoter gene devoid of the TRE region was a nonspecific (ns) probe. (b) ChIP assay as described in Materials and methods section. DNA corresponding to TRE of CTSH promoter region was analyzed by PCR with the indicated primers. Furin or glyceraldehyde 3-phosphate dehydrogenase (GAPDH) promoter region was used as a positive or negative control, respectively. Another positive control was used chromatin before immunoprecipitation (input) and negative controls were immunoprecipitates with MOPC21 antibody. ChIP assays were also performed in HepG2-TRa or b cells. increased in 32.3% (30/93) of the cancerous tissues. Analysis of the CTSH tumor/normal ratio showed no correlation with disease-free or overall survival. Multiple regression analysis was performed using a stepwise model (SPSS version 13.0). The stepping method criteria was set as probability ¼ 0.05 for entry and 0.10 for removal. The T/N ratio of CTSH was associated with being male (b ¼ À0.559; 95% confidence interval (CI) ¼ À0.929-0.188; P ¼ 0.004); albumin level (b ¼ 0.281; 95% confidence interval ¼ 0.017-0.545; P ¼ 0.011); and the presence of microvascular invasion (b ¼ 0.481; 95% confidence interval ¼ 0.112-0.849; P ¼ 0.037). The microvascular invasion characteristic in HCC is closely related to our in vitro characterization of CTSH function. The overexpression of CTSH is not correlated to the hepatitis B virus-caused HCC.
CTSH overexpression promotes cell migration and invasion To determine whether CTSH overexpression increases the metastatic potential in hepatoma cells, we used the parental HCC cell line J7, which expresses the lowest levels of CTSH of the hepatoma cell lines. J7 cells with stable integration of the CTSH gene were selected in media containing G418. Stable clones resistant to G418 were selected, and the levels of cellular and extracellular forms of CTSH protein were measured (Figure 5a ). In a Transwell migration assay, J7 cells stably expressing CTSH in medium containing 1% serum were added to the upper surface of the chamber and allowed to adhere.
Migration was measured for 24 h with medium containing 1% (control) or 10% serum (Figure 5b) . Cells traversing the membrane were stained blue with crystal violet (Figure 5b, lower panel) . The number of transmigrating cells was quantified in three or more separate experiments. Migration was significantly greater in the CTSH-expressing cells. Invasion of J7-CTSH#1, -CTSH#2 or -CTSH-pooled cells was 2-3 times higher than in J7-control cells when assessed using crystal violet staining. The number of invasive cells was quantified (Figure 5c ). These gain-of-function studies showed that CTSH can increase the metastatic potential of hepatoma cells.
T 3 can induce CTSH protein expression in Huh7 cells, which express endogenous TR proteins. To determine whether CTSH is necessary for migration and invasion in hepatoma cells, we reduced CTSH expression in Huh7 cells. Huh7 cells were transfected with a selectable vector expressing CTSH small interfering RNA or a control vector and then selected with puromycin. Stable clones resistant to puromycin were selected, and the levels of the cellular and extracellular forms of CTSH protein were measured (Figure 5d ). Huh7-green fluorescent protein -KD control, Huh7-CTSH-KD#1, -KD#2 and -KDpooled cells, which express very low levels of CTSH, showed less migration and invasion compared with green fluorescent protein-KD cells. Knockdown of CTSH with small interfering RNA led to a 42-54% decrease in migration and 34-43% decrease in invasion (Figures 5e  and f) . These knockdown studies show the functional role of CTSH in invasion and metastasis. 
CTSH overexpression induced by T 3 enhances migration
To determine whether the in vitro results can be applied to the in vivo condition, severe combined immunodeficient (SCID) mice were used. Mice injected with the J7-control and J7-CTSH SCID mice developed multiple macroscopic tumor nodules in the lung (Figure 6a ) as shown by hematoxylin and eosin staining. The metastatic index was 2.3 times higher in the J7-CTSH SCID mice than in the mice injected with J7-control cells. The tumor size relative to the average tumor size (per cm 2 lung section in the J7-CTSH/J7-control mice) was about 4.8 times larger in J7-CTSH SCID mice than in J7-control mice. CTSH protein expression, shown as a dark-brown color in immunohistochemical staining, was markedly stronger in J7-CTSH lung tumors than in J7-control tumors. To verify further whether CTSH is involved in T 3 -mediated migration, we reduced CTSH expression in HepG2-TRa#1 and Huh7 cells using CTSH small interfering RNA, which knocks down CTSH expression. CTSH small interfering RNA decreased the T 3 -mediated migration in HepG2-TRa#1 and Huh7 cells (Figure 6b ). To verify whether antibody against CTSH prevents the cellular response, similar migration experiments were performed. Anti-CTSH antibody but not anti-green fluorescent protein antibody reduced the T 3 -mediated cell migration in HepG2-TRa#1 and Huh7 cells (Figure 6c ).
To determine whether MMPs are potential downstream mediators of CTSH, both pro-MMP-9 (97 kDa) and pro-MMP-2 (72 kDa) were studied in J7-derived Figure 6 Mediated overexpression of CTSH by thyroid hormone promotes hepatocyte migration. (a) J7-control or J7-CSTH SCID mice (n ¼ 4 per group) were established. All analyses were carried out 7 weeks after inoculation of tumor cells. Immunohistochemical staining of metastasized J7-control or J7-CSTH cells in lung sections are displayed. The metastasis index (fold, density of tumor numbers in J7-CSTH or J7-control per cm 2 area) in lung is shown in the lower panel. (b) Effect of T 3 -mediated migration activity in HepG2-TRa#1 and Huh7 cells, which knocked down CTSH expression. HepG2-TRa or Huh7 cells were transient transfected with either control (luc short hairpin RNA (shRNA)) or CTSH shRNA by electroporation. After puromycin selection, stable clones were pooled for migration assay. The cell lines were added to the upper chamber of Transwell units and incubated in the absence or presence of T 3 (10 nM) for 24 h. The number of cells that transversed the filter to the lower chamber was then determined and expressed as the relative migration activity. (c) Effect of anti-green fluorescent protein (GFP) or anti-CTSH antibody treatment on migration activity in HepG2-TRa#1 and Huh7 cells. The cell lines were added to the upper chamber of Transwell units and incubated in the absence or presence of T 3 (10 nM) and anti-GFP or anti-CTSH antibody (10 mg/ml) for 24 h. (d) Two different control cell clones (J7-control#1 and J7-control#2) that stably express neo proteins and two J7-CTSH stable clones were used for MMP assays. J7-control or J7-CSTH cells (2 Â 10 6 ) were plated in Dulbecco's modified Eagle's medium (DMEM) with 10% fetal bovine serum. After 24-h incubation and subsequent washing, the medium was replaced with serum-free medium. Medium was collected for MMP detection. Gelatin zymography was performed; the position of proenzyme and active form of MMPs is shown to the left. (e) HepG2-TRa#1 and J7-derived cells were treated in serum-free medium and were incubated in T 3 (0, 1 and 10 nM) for 24 or 48 h. Medium was collected for western blot analysis of MMP3. (f) J7-control or J7-CSTH cells were cultured in serum-free medium for 24 h. Cell lysates were western blotted with anti-ERK and anti-phospho-ERK antibodies. Actin was used as an internal control. (g) HepG2-TRa#1 or Huh7 cells were stimulated to migrate T 3 by in the presence or absence of indicated MEK inhibitors (U0126). The relative migration means that in response to T 3 ( þ or -inhibitor) normalized to dimethylsulphoxide (DMSO) treated, T 3 -deprived controls. Data are means ± s.e. of values from three independent experiments. cells. Gelatin zymography revealed that CTSH-induced MMP-2 activity and cleaved pro-MMP-2 to MMP-2 (Figure 6d ). Western blot analysis of pro-MMP-3 and MMP-3 protein expression demonstrated an increase in the active form of MMP-3 in T 3 -stimulated HepG2-TRa#1 cells. Similarly, MMP3 was activated in J7-CTSH cells (Figure 6e) . Phosphorylation of extracellular signal-regulated kinase (ERK) regulates the association of focal adhesion kinase, and paxillin is involved in focal adhesion. ERK might also have a role in cell migration by inhibiting the ability of integrins to bind to their extracellular matrix ligands (Teranishi et al., 2009) . To study whether the CTSH-mediated signaling involves phosphorylation, p-ERK and total ERK levels were measured. ERK was phosphorylated in J7 cells, which overexpress CTSH (Figure 6f ). We also tested the effect of U0126, an inhibitor of mitogen-activated protein kinase (MAPK) kinase (MEK) activation and MEK catalytic activity (Figure 6g ). Cells were pretreated with U0126 or dimethylsulphoxide for 15 min before treatment with 10 nM T 3 for an additional 24 h. U0126 decreased T 3 -mediated migration in HepG2-TRa#1 and Huh7 cells. These data are consistent with the role of ERK in T 3 -stimulated migration. Taken together, the results show that T 3 -mediated upregulation of CTSH led to MMP or ERK activation and increased cell migration.
Discussion
This study characterized CTSH, which was identified previously in microarray screening for T 3 -responsive genes in HepG2-TR cells. However, the transcriptional regulation of the human CTSH gene was not elucidated in previous studies. We attempted to elucidate the molecular mechanism of CTSH regulation by T 3 in isogenic HepG2 cell lines. Our study indicates that T 3 -induces CTSH expression at both the mRNA and protein levels in HepG2 cell lines. Similar results were observed in Huh7 cells, which expressed detectable endogenous TR proteins and in thyroidectomized rats. Further study demonstrated that T 3 upregulates CTSH at the transcriptional level. The promoter assay and EMSA findings suggest that TR activates CTSH gene transcription by binding directly to the two TRE sites located in the À2038 to À1966 and À1565 to À1501 regions. The ChIP assay revealed that the TRs and RXRa complex bound to the CTSH promoter. Although our study investigated T 3 -induced CTSH expression in human hepatoma cell lines, similar results have been obtained in animal studies.
Although the role of CTSH in tumor progression is not understood well, a possible function of CTSH in tumor progression is its ability to degrade fibrinogen and fibronectin. CTSH and other proteases may be involved in the destruction of extracellular matrix components, leading to cancer proliferation, migration and metastasis (Tsushima et al., 1991) . Similar induction by T 3 of extracellular CTSH protein was observed in HepG2-TR and Huh7 cells. As HepG2 cells express very low levels of endogenous TR proteins, CTSH was not significantly induced by T 3 in HepG2-neo cells. However, another hepatoma cell line, Huh7, which express relatively high levels of TR proteins and T 3 can induce CTSH proteins expression in these cells. The gain-offunction studies showed that CTSH can increase the metastatic potential of hepatoma cells. Our results show that CTSH overexpression in some HCCs may be TR dependent and that this overexpression might have an important role in HCC progression. Taken together, these results suggest that T 3 regulates CTSH gene expression, thereby enhancing cancer invasiveness.
Cathepsins belong to the class of proteases in the complex interplay between tumor and stroma. A majority of cathepsins are lysosomal proteases, but some are secreted or membrane associated. The intracellular active form (28-kDa) of CTSH is autocatalyzed from the 41-kDa pro-form at acidic pH conditions and localized within the intercellular compartments (Turk et al., 2000; Dickinson, 2002) . The secreted CTSH exists predominantly in a pro-form in the medium. Here, we showed an increase in both of the 28-or 41-kDa form of CTSH in HepG2-TR cells after T 3 treatment. However, the trafficking or sorting mechanisms of CTSH need to be clarified.
Schraufstatter et al. reported that interleukin-8-induced transactivation of the epidermal growth factor receptor is mediated by CXCR2 and involves CTSB, and that this pathway is important for the migratory and tumorigenic effects of interleukin-8 (Schraufstatter et al., 2003) . We used oligonucleotide microarrays and found that the expression of interleukin-8 and CTSB was induced by T 3 in HepG2-TR cells (Supplementary  Table S1 ). Using HepG2-TR and Huh7 cells, which express endogenous TR, we also found that T 3 enhances the metastatic ability of hepatoma cell lines. These results show that T 3 enhances the migratory and invasive properties of hepatoma cell lines.
A previous study indicated that T 3 , acting through TRs, inhibits the expression of NM23-H1 and promotes tumor metastasis (Lin et al., 2000) . Thyroid hormone and TRa1 control epithelial cell proliferation and the expression of components of the Wnt pathway (Plateroti et al., 2006) . The expression of the b-catenin and sFRP2 gene is regulated directly by TRa1, and the Wnt/ b-catenin signaling networks contribute to intestinal tumorigenesis (Kress et al., 2009) . Chiloeches et al. (2008) reported that ERK but not c-Jun N-terminal kinase or p38-MAPK is activated on exposure to T 3 in rat pituitary tumor (GH4C1) cells. In general, ERK has been implicated in the migration of numerous cells . In our study, T 3 -mediated ERK activation was observed in HepG2-TRa1 cells and in parallel with the phosphorylation of ERK in J7 CTSHoverexpressing cells. Treatment of HepG2-TRa1 or Huh7 cells with U0126 inhibited the migration in response to T 3 . We demonstrated previously that T 3 regulates furin gene expression via a newly identified mechanism or in cooperation with transforming growth factor-b to enhance tumor metastasis in vitro and in vivo (Chen et al., 2008a) . T 3 and transforming growth factor-b regulate furin gene expression directly, thereby enhancing the invasiveness of liver cancer cells in SCID mice models.
The role of TRs in cancer progression appears to be multifaceted. Recent report showed that hypothyroidism was associated with a high risk of HCC in women (Hassan et al., 2009) (Kress et al., 2010) . However, TRa1 when specifically overexpressed in the intestinal epithelium is unable to induce cancer development. Conversely, the investigators observed that TRa1 accelerated tumorigenesis in mice with a Wnt-activated Apc þ /1638N genetic background. These divergent actions of TRs in HCC development possibly result from varying tissue-and stage-specific microenvironments.
Previously, we reported that TRs might have a suppressor role by reducing PTTG1 and Sp1 expression (Chen et al., 2008b) . Knockdown of these genes inhibited HepG2-TRa1 cell growth in parallel with T 3 -mediated HepG2-TRa1-induced cell growth inhibition. However, furin and CTSH expression levels were positively regulated by T 3 in parallel with T 3 -mediated HepG2-TRa1 cell migration. These contradictory results in cancer progression suggest that the final roles of TRs in liver cancer might depend on reciprocal actions on tumor cells and on other cellular regulators on the tumor milieu. Tumor-infiltrating cells orchestrate the microenvironment and provide growth factors, proangiogenic factors and proteases, as well as adhesion molecules that facilitate tumor cell proliferation, angiogenesis and migratory activity (Nelson and Ganss, 2006) . Interestingly, one of the TRb1 interacting partners, transforming growth factor-b, works both as a tumor suppressor and a tumor promoter (Yang and Moses, 2008) . Therefore, further studies are necessary to investigate what factors might mediate the switching of the functions of TRs in the microenvironment of HCCs.
Here, we found that CTSH is also regulated directly by T 3 in human hepatoma cell lines and that it can enhance the metastatic potential of hepatoma cells. T 3 also stimulates MMP2 and MMP3 activation, in parallel with the CTSH-mediated migration, by increasing MMP activity. The studies discussed above and this report shows that TR is a potential tumor promoter in tumorigenesis. CTSH and furin or other proteases may be involved in liver cancer progression. Our current data extend our previous results showing that T 3 has a role in cancer progression. Although CTSH expression is upregulated in some types of HCC, its significance requires further study.
Materials and methods

Cell culture
The human hepatoma cell lines (HepG2 and its isogenic lines, Huh7, and J7) were routinely grown in Dulbecco's modified Eagle's medium supplemented with 10% (v/v) fetal bovine serum. Serum was depleted of T3 by AG 1-X8 resin (Bio-Rad, Hercules, CA, USA) as described elsewhere (Samuels et al., 1979) . Cells were cultured at 37 1C in a humidified atmosphere of 95% air and 5% CO 2 . Both HepG2 and Huh7 cell lines are well differentiated; J7 is intermediately differentiated. T3 was purchased from Sigma-Aldrich, St Louis, MO, USA. For T 3 induction, cells were exposed to 1 and 10 nM T 3 for 24, 48 and 72 h, respectively, after 24 h cultured in the T 3 -depleted-medium.
Quantitative reverse transcription-PCR
Real-time quantitative reverse transcription-PCR was conducted in a 15 ml reaction mixture containing 25 nM forward and reverse primers, 1 Â SYBER Green reaction mix (Applied Biosystems, Carlsbad, CA, USA), and varying quantities of template as described previously (Shih et al., 2004) . The sequences of primers used in quantitative real-time PCR listed in Supplementary Table 2 .
Northern blot analysis Total RNA was extracted from the cells with TRIzol Reagent (Life Technologies Inc., Carlsbad, CA, USA). Equal amounts of total RNA (20 mg) were analyzed on a 1.2% agaroseformaldehyde gel. Separated RNA molecules were then transferred to a nitrocellulose membrane and subjected to Northern blot analysis as described previously (Huang et al., 2006) . Intensities of the CTSH mRNA bands on blots were quantified, and the degree of the T 3 -induced increase in CTSH transcripts were determined at each point. The signals were assayed for CTSH mRNA expression level after normalizion with 18S rRNA using FujiFilm image gauge V3.46 analysis software (Fuji Film, Tokyo, Japan).
Immunoblot analysis
Cells were lysed in lysis buffer (25 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% sodium dodecyl sulfate) containing protease inhibitors (aprotinin, leupeptin and PMSF) on ice, and centrifuged at 10 000 Â g at 4 1C for 30 min. The supernatant was transferred to a new tube. Total cell lysates (20 mg per lane) were fractioned by SDS-polyacrylamide gel electrophoresis on a 10% gel. Separated proteins were transferred to a nitrocellulose membrane and visualized by chemiluminescence using an ECL detection kit (Amersham Inc., Piscataway, NJ, USA) as described previously (Liao et al., 2009 ). The antibodies used were goat polyclonal antibodies to CTSH (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA). The intensities of the immunoreactive bands were quantified using Image Gauge software (Fuji Film).
Animals
Twelve male Sprague-Dawley rats underwent TX at 6 weeks of age according to method used in previous reports (Yang et al., 1999) . Before removing the thyroid gland, the anterior and posterior thyroid arteries were ligated, and the external parathyroid glands were carefully isolated during removal of the thyroid gland. Sham operations were performed under the same conditions except that the thyroid, parathyroid glands and the blood supply to the glands were kept intact. Each rat was given 1% calcium lactate in drinking water after surgery. Two weeks after surgery, each rat was intraperitoneal injection with T 3 at 10 mg per 100 g body weight or a control vehicle (2.5 mM NaOH in phosphate-buffered saline) daily for 2 further weeks. Rats were killed at the end of the experiment, and their serum was used for T 3 and TSH determination. The expression levels of mRNA and proteins in the liver were analyzed by quantitative reverse transcription-PCR and western blot, respectively. All animal experiments in this study were performed in accordance with National Institutes of Health guidelines and the Chang-Gung Institutional Animal Care and Use Committee Guide for Care and Use of Laboratory Animals.
Transient transfection and luciferase assays
To clone the CTSH 5 0 -flanking region and promoter activity assay, fragments of the CTSH promoter (nucleotides À2723 to þ 52) were amplified using PCR according to the published nucleotide sequence and then inserted into the pA3TK-Luc vector. Transient transfection in HepG2 cells was performed by the lipofectamine transfection method using as described (Wu et al., 2010) . We used vector NTI v7 software (Invitrogen Inc., Carlsbad, CA, USA) for possible TRE sequences analysis and CTSH gene promoter sequence in Supplementary Figure S3 .
Effect of knocked-down CTSH expression
The clone TRCN0000003699 of short hairpin RNA targeting CTSH was purchased from the National RNA Interference Core Facility (Institute of Molecular Biology, Academia Sinica, Taipei, Taiwan). Electroporation was performed in BTX ECM 600 electroporator (BTX Inc., San Diego, CA, USA). Cells (70-80% confluent) were trypsinized, centrifuged and suspended in 400 ml of Dulbecco's modified Eagle's medium containing 2.5% FBS. Subsequently, 15 mg short hairpin RNA plasmid was added and transferred to 4 mm gap electroporation cuvettes. Cells were plated in 10-cm dishes after pulsing. After 16 h, medium was changed with Dulbecco's modified Eagle's medium containing puromycin for stable clone selection.
Electrophoretic mobility shift assay
The wild-type CTSH gene probe, which encompassed nucleotides À2038 to À1966 and À1565 to À1501 of the CTSH promoter, was used for EMSA probes. The normal TRE sequence 5 0 -AGGGCACAGAGGCTCA-3 0 of the CTSH promoter À2038 to À1966 and mutant sequence 5 0 -GGGGGG CAGAGGGGGG-3 0 were labeled with [a-32 P-dCTP] by PCR reaction following gel purification. The normal TRE sequence 5 0 -AGGGCATCACTGGGCA-3 0 of the CTSH promoter À1565 to À1501 and mutant sequence 5 0 -GGGGGGTCACG GGGGG-3 0 were also labeled with [a-32 P-dCTP]. EMSA was performed as described previously (Lin et al., 2000) . C4 mouse monoclonal antibody to TRs (sc-740, Santa Cruz Biotechnology Inc.), rabbit polyclonal anti-body to RXR (sc-553, Santa Cruz) and MOPC21 mouse monoclonal antibody (ICN Biomedicals, Aurora, OH, USA) as a negative control for EMSAs.
Chromatin immunoprecipitation
ChIP assay was performed as described previously . The upstream TRE region of the human CTSH gene was amplified with the forward primer 5 0 -AAAGAGAGGGA AGGGCACAG-3 0 at nucleotide À2038 and reverse primer 5 0 -AGTGATCCTCCTGCCTCA-3 0 at nucleotide À1966. A proximal TRE region was amplified with the forward primer 5 0 -AGTGAAGAACAGGGCATC-3 0 at À1565 and reverse primer 5 0 -AGAGG GTGATTCAGACCA-3 0 at À1501. The TRE region of furin promoter was amplified with forward primer 5 0 -TACTAGCGGTTTTACGGGCG-3 0 and reverse primer 5 0 -TCGAACAGGAGCAGAGAGCGA-3 0 for positive control. The 166-bp pair product of glyceraldehyde 3-phosphate dehydrogenase promoter without TRE was amplified with forward primer 5 0 -CTCCAAAGACCCACTGCG-3 0 and reverse primer 5 0 -CCACTTGTCCTC AGGCCTAG-3 0 for a negative control. C4 mouse monoclonal antibody to TRs and rabbit polyclonal antibody to RXRa (Santa Cruz) were used for ChIP analysis.
Zymography
In all, 20 mg of concentrated medium was diluted in 50 mM Tris-HCl (pH 7.4) without a reducing agent and separated by 10% SDS-polyacrylamide gel electrophoresis in the presence of 1 mg/ml gelatin as described (Chen et al., 2008b) .
Migration and invasion assays
Hepatoma J7 cells were transfected with the pcDNA-CTSH expression vector, and the J7 stable line-expressing CTSH was identified by G418 selection. To establish CTSH knockdown, we used the stable hepatoma Huh7 cell line and the clone TRCN0000003699 of short hairpin RNA targeting CTSH from the National RNA Interference Core Facility (Institute of Molecular Biology, Academia Sinica). Cell migration was studied using a modified two-chamber migration assay (Falcon BD, Franklin Lakes, NJ, USA) with a pore size of 8 mm as described .
Murine models of tumor progression and metastasis SCID mice were used to determine the invasive ability of the CTSH-overexpressing J7 cells. J7-vector and J7-CTSH cells (each 1 Â 10 7 ) were injected intravenously. All animals were killed in the seventh week after tumor inoculation, whereupon the liver and lungs were removed. All animal experiments were performed in accordance with United States National Institutes of Health guidelines and the Chang-Gung Institutional Animal Care and Use Committee Guide for Care and Use of Laboratory Animals.
Formalin-fixed and paraffin-embedded tissues from the livers or lungs of SCID mice were examined by immunohistochemistry using a polyclonal antibody to CTSH (Proteintech Group, Inc., Chicago, IL, USA) following the avidin-biotin complex method as described previously (Chen et al., 2008a) . Positive staining, indicating cancer cells, appeared as a darkbrown color showing CTSH immunoreactivity.
Human HCC specimens With informed consent, 93 patients with HCC diagnosed between 2000 and 2003 were selected consecutively for this study. All samples of HCC tissues with paired adjacent normal liver tissues (B1 cm distant from the HCC biopsies) were obtained during surgical resection from the Chang Gung Memorial Hospital medical research center for western blot analysis. HCC and adjacent noncancerous liver tissue samples were confirmed by histopathology. The study protocol was approved by the Medical Ethics and Human Clinical Trial Committee at Chang-Gung Memorial Hospital.
Statistical analysis
Values are expressed as mean±s.e. of at least three independent experiments. Statistical analysis of data was carried out using Student's t-test. **Po0.01; *Po0.05. Po0.05 was considered statistically significant.
